Todas las investigaciones
ReclutamientoFase IIIIntervencionista

Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema

Researchers are studying a new medicine called navenibart for hereditary angioedema (HAE), a condition causing unpredictable swelling attacks. These attacks can be very painful and disabling. Navenibart is designed to help prevent these attacks. This study, called ORBIT-EXPANSE, is particularly interested in checking the safety and how well people cope with navenibart over a long period, up to five years. It's for adults and teenagers (aged 12 and older) who have already taken part in a previous navenibart trial (ALPHA-ORBIT). The information gathered will help improve future treatments for HAE, even if there's no direct benefit for every individual participant.

De un vistazo

Estado
Reclutamiento
Fase
Fase III
Patrocinador
Astria Therapeutics, Inc (USA)
Objetivo de inscripción
145
Inicio
12 Feb 2026
Estimación de finalización
31 Dic 2026

¿De qué trata este estudio?

Hereditary angioedema (HAE) is a rare condition that causes sudden and painful swelling. These swelling attacks can affect different parts of the body, like the face, arms, legs, and even the throat, which can be very serious. Currently, people with HAE take medicines to stop attacks once they start, or to prevent them from happening. However, sometimes these treatments need to be taken very often, which can be difficult for patients.

This study is looking at a new medicine called navenibart. Navenibart is a type of medicine that works with your body's immune system. It aims to prevent HAE attacks by blocking a specific natural process in the body that causes the swelling. Early studies have suggested that navenibart could be helpful in preventing these attacks. The company that makes navenibart, Astria Therapeutics, wants to learn more about how it works in people with HAE.

The main goal of this study, called ORBIT-EXPANSE, is to understand how safe navenibart is and how well people tolerate it when taken over a long time. This includes both adults (18 and older) and teenagers (12-17 years old). Participants will be in the study for up to five years. The information gathered from this research will help doctors and scientists better understand HAE and develop more effective and convenient treatments in the future.

Puntos clave

  • New medicine (navenibart) for hereditary angioedema (HAE) is being studied.
  • Aims to check long-term safety and how well people tolerate the medicine.
  • For adults and teenagers (12+) who completed a previous navenibart study (ALPHA-ORBIT).
  • Participants will receive navenibart through under-the-skin injections.
  • Study could last up to five years.
  • Results will help improve future HAE treatments.

¿Quién puede ser elegible?

This study is for people who have hereditary angioedema (HAE) and have already taken part in a previous study for navenibart called ALPHA-ORBIT (STAR-0215-301). You would have either completed the ALPHA-ORBIT study or left it early but still received at least two doses of the study medicine and had at least two months of follow-up after the second dose.

You cannot take part if you have been in another medical study (apart from ALPHA-ORBIT) in the last 30 days, or if you've had certain study medicines (other than navenibart) recently. Also, if you've taken certain blood pressure medicines (called ACE inhibitors) or hormone-containing medicines (like some contraceptives or hormone replacement therapy) in the last 30 days, you won't be able to join.

Finally, if you know you are allergic to any of the ingredients in navenibart, this study would not be suitable for you. The study is open to both men and women, aged 12 years and older.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I have hereditary angioedema (HAE).
  2. I previously took part in the ALPHA-ORBIT study (STAR-0215-301).
  3. I completed the ALPHA-ORBIT study or met specific criteria if I left it early.
  4. I have not taken part in another recent medical study (apart from ALPHA-ORBIT).
  5. I have not recently used certain blood pressure or hormone medicines.
  6. I am not allergic to any ingredients in navenibart.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, your involvement could last for up to five years. All participants will receive the study medicine, navenibart, which is given as an injection just under the skin.

For adults who were in the ALPHA-ORBIT study, the first part of this new study will last at least six months. If you received navenibart in ALPHA-ORBIT, you'll continue with the same dose. If you received a placebo (a dummy treatment) in ALPHA-ORBIT, you'll start receiving 600mg of navenibart every three months. After this first part, adults may be able to discuss changing their dose with the study doctors. Teenagers in the study will continue to receive navenibart at the same dose they had in the ALPHA-ORBIT study.

Riesgos y beneficios potenciales

It's important to know that taking part in this study may not directly improve your HAE or provide a personal medical benefit. Your HAE might get better, stay the same, or even get worse. However, the information learned from this study is very valuable and will help researchers better understand HAE and develop improved treatments for everyone with the condition in the future. As with any medicine, there is a possibility of side effects from navenibart, but the study aims to carefully monitor and understand these over the long term. You are free to withdraw from the study at any time.

Ubicaciones (6)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • Fundación de Salud NHS de Frimley
    Solo ciudad
    Camberley, England
  • Barts Health NHS Trust
    Solo ciudad
    London, England
  • North Bristol NHS Trust
    Solo ciudad
    Bristol, England
  • Royal Free London NHS Foundation Trust
    Solo ciudad
    London, England
  • University Hospitals Plymouth NHS Trust
    Solo ciudad
    Plymouth, England
  • Cambridge University Hospitals NHS Foundation Trust
    Solo ciudad
    Cambridge, England

Preguntas comunes

¿Qué es el angioedema hereditario (HAE)?

HAE is a rare genetic condition that causes sudden, unpredictable, and often painful attacks of swelling in different parts of the body.

What does navenibart do?

Navenibart is a new medicine being studied to help prevent HAE attacks by blocking a natural process in the body that leads to swelling.

How is navenibart given?

Navenibart is given as an injection just under the skin, using a small needle.

¿Cuánto tiempo estaré en el estudio?

If you join, your participation could last for up to five years.

Will I definitely receive the study medicine?

Yes, all participants in this study will receive navenibart.

Cómo obtener más información

. Clinical Trial Inquiries

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Astria STAR-0215-302 trial for Navenibart in Hereditary Angi…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.